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IMMUNE EVENTS FOLLOWING IMMUNOABLATIVE THERAPY FOR THE
TREATMENT OF MULTIPLE SCLEROSIS (MS)
Atkins, H.1, Freedman, M.1, Bowman, M.1, Bar-Or, A.2, Cheynier,
R.2, Corsini, R.2, Jalili, F.3, Kim, H.J.3, Miller, L.3, Sekaly, R.3,
Canadian MSBMT Study Group. 1. The Ottawa Hospital, Ottawa, ON,
Canada; 2. Montreal Neurological Institute of McGill University, Mon-
treal, QC, Canada; 3. University of Montreal, Montreal, QC, Canada
This report details the immunology of the ﬁrst patient enrolled
in the Canadian trial of immunoablative therapy with autologous
stem cell transplantation (SCT) for MS. This trial tests the concept
that immunoablative therapy can stop autoimmunity in MS and
halt further CNS damage. Furthermore reconstitution of a naïve
immune system should be functional and self-tolerant. A 31-year-
old woman with secondary progressive MS underwent a CD34
selected autologous SCT after receiving Busulphan (16 mg/kg),
Cyclophosphamide (200 mg/kg) and rabbit ATG (5 mg/kg). MS
Activity: The patient is clinically stable 24 mo. post SCT with no
relapses or progression of disabilities. There is sustained resolution
of gadolinium activity and improved T2 metrics by MRI. Thus MS
activity has been shut down. Immune ablation: The patient be-
came lymphopenic. All lymphocyte subpopulations were de-
creased. There was loss of humoral immunity to mumps and
measles at 18 mo. post SCT and lost cutaneous reactivity to
candida at 6 and 12 mo. post SCT. Antigen speciﬁc in vitro T cell
responses to myelin basic protein (MBP), tetanus toxoid (TT) and
copaxone (GA) were reduced or abolished following SCT. There
was 1000 fold reduction in recent thymic emigrants 3 mo. post
SCT and a reduction in circulating naı¨ve T cells. Thus immuno-
ablation was achieved. Immune reconstitution: The patient has
not developed opportunistic infections. The lymphocyte count has
slowly risen during the post SCT period. Both helper and suppres-
sor populations remain profoundly low with mainly a memory
phenotype. The CD4:CD8 ratio normalized at 12 mo. post SCT.
Thymic emigrants in the circulation have increased to about 10%
of baseline. B cell and immunoglobulin levels are normal. Humoral
immunity is polyclonal. A positive cutaneous response to candida
antigen testing occurred 24 mo. post SCT. Speciﬁc in vitro T cell
responses to TT following reimmunization are currently being
evaluated. This preliminary data suggests that the post transplant
immune system is protective and self-tolerant. The data from this
patient indicates that complete immunoablation was achieved and
is associated with a signiﬁcant change in MS activity. The patient
remains lymphopenic but is not prone to opportunistic infections.
Immune reconstitution is ongoing and is NOT associated with
recurrence of MS activity.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TAKA-
YASU’S ARTERITIS: REPORT OF THE FIRST CASE OF THE LITERATURE
Voltarelli, J.C., Oliveira, M.-C.B., Stracieri, A.-B.P.L., Godoi, D.F.,
Moraes, D.A., Coutinho, M.A. Hospital das Clinicas-Univ. Sao Paulo,
Ribeirao Preto, Estado de Sao Paulo, Brazil
The ﬁrst reports of hematopoietic stem cell transplantation
(HSCT) for isolated autoimmune diseases appeared in 1996 and
since then about 700 patients were transplanted. However, very
few patients with vasculites were submitted to HSCT, and all
patients had small or medium size arteritis (1) Fiehn Hensel, High
Dose Chemotherapy with Hematopoietic Stem Cell Transplanta-
tion in Primary Vasculitis, Behcet’s Disease and Sjogren Syn-
drome, in Burt R, Marmont A, eds, Stem Cell Transplantation for
Autoimmune Diseases, Landes Bioscience, in press, 2) Marmont et
al, Bone Marrow Transplantation 31, Suppl 1, S15-16, 2003). We
report here the case of a 41 year old woman with Takayasu’s
arteritis presenting since June 1990 with constitutional symptoms,
polyarthritis, myalgia, dizziness, upper and lower limb claudication
and transient visual impairment. Arteriography showed irregularity
and stenosis of abdmonial aorta, right and left iliac arteries, left
subclavia and carotid arteries. The disease had been treated for 13
years with steroids (PO and IV) and several other immunosupres-
sive agents (methotrexate, cyclophosphamide, chlorambucil and
mycofenolate mophetil) without response. In March 2003, autol-
ogous peripheral blood hematopoietic stem cells were mobilized
with cyclophosphamide (2 g/m2) and G-CSF (10 ug/kg/d), cryo-
preserved and infused (3.9 million/kg) one month later after con-
ditioning with cyclophosphamide (50 mg/kg 4) and rabbit anti-
thymocyte globuline (1,5 mg/kg3). Posttransplant complications
were diarrhea, neutropenic fever and emotional liability, neutro-
phil engraftment occurred at D9 and discharge was on D16.
On D60 the symptoms had improved signiﬁcantly and an an-
gioressonance showed dramatic reduction of brachiocephalic ar-
tery stenosis and carotid arteries irregularities. This rapid improve-
ment suggests that aggressive immunosuppression caused the
observed therapeutic effect in this case but induction of tolerance
and tissue repair mediated by stem cells may operate long term.
This is the ﬁrst case of a large size arteritis treated with HSCT and
illustrate the therapeutic potential of high dose immunosuppres-
sion and cellular therapy in severe vasculitis.
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CAN THE STEM CELL MOBILIZATION TECHNIQUE INFLUENCE CD34
CELL COLLECTION EFFICIENCY OF LEUKAPHERESIS PROCEDURES IN
PATIENTS WITH HEMATOLOGIC MALIGNANCIES?
Gidron, A., Verma, A., Doyle, M., Villa, M., Shook, T., Gordon, L.,
Singhal, S., Tallman, M., Williams, S., Winter, J., Mehta, J. North-
western University, Chicago
CD34 cell collection efﬁciency (CE) reﬂects the proportion of
CD34 cells that is harvested during apheresis. Higher CE results
in a bigger stem cell collection per procedure; reducing the number
of procedures required to reach the target. 415 leukaphereses done
on 201 patients (1-11 each; median 2) using Cobe Spectra cell
separators over 26 months were studied to determine CD34 cell
CE. Apheresis was done for leukemia (n  54), lymphoma (n 
130), and plasma cell dyscrasias (n  231). Aphereses done with
pre-apheresis peripheral blood CD34 cell count (PBCD34)
0.02% were excluded to reduce variability and calculation error.
Stem cells were mobilized with growth factor (GF; n  119) or
chemotherapy-GF (n 296). 15 (n 202) or 20 (n 213) L blood
volume was processed. The pre-apheresis WBC count was 1-93 
109/L (median 20), and PBCD34 was 1-1104/mm3 (median 19).
The total number of CD34 cells collected was 4-6531  106
(median 151); corresponding to 0.1-111.4  106 (median 2.3) per
kg. There was strong correlation between PBCD34 and the num-
ber of CD34 cells collected (r2  0.80; P  10100). CE was
7-145% (median 46). On multiple regression analysis, higher
WBC (continuous variable; P  0.0001), higher PBCD34 (contin-
uous variable; P  0.009), and greater blood volume processed
(categoric variable; P  0.02) resulted in lower CE. Age, sex,
weight, diagnosis, year, mobilization technique, Hct, and platelets
did not affect CE. PBCD34 counts were higher (median 22 vs 15;
P 0.036) in patients mobilized with chemotherapy-GF compared
to GF alone despite lower WBC counts (median 16 vs 30; P 
0.0001) because of higher %PBCD34 (median 0.16% vs 0.05%;
P  0.0001). CE with WBC 20 was 7-145% (median 53%)
compared to 10-132% (median 40%) with WBC 20 (P  0.0001),
suggesting that WBC 20 may be optimum for apheresis in terms
of maximizing CE. Since PBCD34 increases early during WBC
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recovery after chemotherapy, 61% of the apheresis procedures
performed after chemotherapy-GF occurred when WBC was 20
compared to 21% of those performed after GF alone (P 0.0001).
With GF alone, mobilization is optimal after 4-5 days of therapy
when WBC is likely to be 20. We conclude that mobilizing
patients with the combination of chemotherapy and GF rather
than GF alone is likely to lead to leukapheresis being performed
when theWBC count is in a range that results in optimum CD34
cell CE. Autologous stem cells should be mobilized with chemo-
therapy-GF rather than GF alone if this is clinically feasible.
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A LONG TERM FOLLOW UP STUDY OF AUTOLOGOUS TRANSPLANTA-
TION FOR FOLLICULAR LYMPHOMA: A SINGLE CENTER EXPERIENCE
Ganguly, S., Deauna-Limayo, D., Divine, C.L., Bodensteiner, D.C.,
Cook, J.D., Lewis, J.L., Skikne, B.S. University of Kansas Medical
Center, Kansas City, KS
Appropriate timing of transplant in the management of follicular
lymphoma (FL) is not clear. We retrospectively evaluated our
experience of autologous transplantation in patients with FL from
1991 to 2003. Seventeen males and 7 females (n  24) of median
age 47.5 years (range, 28-64 years) were treated. Three patients
were in ﬁrst remission. Twenty one patients were salvaged after
relapse with second line chemotherapy. Of these, 14 were in CR or
very good PR at the time of transplantation, and 7 patients were
transplanted with active disease. Bone marrow was used in 6 pa-
tients as the source of stem cells prior to 1995 and peripheral blood
stem cells were used in 18 patients. The median CD34 cell dose
was 2.97  106/kg (range, 2.22-7.49  106/kg). Twenty-three of
24 patients engrafted (96%). Median time for neutrophil recovery
was 11.5 days (range, 9-35 days) and 15 days (range, 10-40 days) for
platelets. Median duration of follow up was 6 years (range, 7
month-8 years). Of the 24 patients, 6 had died. One patient died
from transplant related pulmonary complication. Overall survival
(OS) and disease free survival (DFS) of all evaluable patients were
71.6% and 40%. Median duration of response was 4.3 years. OS
and DFS in patients transplanted in CR were 80% and 57%. For
those transplanted with disease, a complete response was achieved
in 43% of patients, with the OS and DFS of 57% and 19 %
respectively. Status at transplantation was not a signiﬁcant variable
for survival (p 0.3). Three patients developed moderate to severe
treatment related toxicity; 2 with Grade III mucositis and 1 with
life threatening infection. In our experience, high dose therapy
with autologous stem cell transplantation in patients with high risk
or relapsed/refractory FL has little toxicity and appears to be
effective. Those with more advanced disease may require addi-
tional approaches to achieve and maintain remission.
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NON-MELPHALAN BASED CONDITIONING REGIMENS FOR TANDEM
AUTOGRAFTS IN MULTIPLE MYELOMA PATIENTS
Moreb, J.S., Pumphrey, P., Khan, S.A., Leather, H., Finiewicz, K.J.,
Reddy, V.S., Wingard, J.R. University of Florida, Gainesville, FL
Autologous stem cell transplantation (ASCT) has become a stan-
dard therapy for multiple myeloma (MM) patients. In the current
study we evaluated the toxicity and efﬁcacy of tandem autografts
for MM patients using non-melphalan based conditioning regi-
mens. Patients with stage II and III MM were enrolled in the study
after exhibiting response to induction therapy. The treatment plan
was designed to harvest a dose of 10  106 peripheral blood
CD34 cells/Kg ideal body weight (IBW) for the planned 2
transplants; however, a 2nd ASCT would be pursued only if CR has
not been achieved after the 1st ASCT. The 1st conditioning regi-
men included Busulfan 0.75 mg/Kg PO q6h for 16 doses on days
-8 through -5, Etoposide 10mg/Kg IV on days -4 to -2, and
Cyclosphosphamide 60 mg/Kg IV on days -3 and -2. The condi-
tioning regimen for the 2nd ASCT included 96 hour continuous
infusion of Cyclophosphamide (6 gr/m2) followed by total body
irradiation of 600 cGy in 4 fractions over 2 days followed by
reinfusion of stem cell product. Thus far, 21 patients have been
enrolled, median age of 56 years with median of 191 days from
diagnosis to 1st ASCT. All patients completed stem cell harvest
successfully. Total of 11 patients did not proceed to 2nd ASCT: 7
patients refused 2nd ASCT, 3 patients had CR after 1st ASCT, and
1 patient was disqualiﬁed due to drug induced psychosis during 1st
ASCT. Two patients are currently undergoing 2nd ASCT. Eight
patients completed tandem autografts. Median CD34 cell dose
and engraftment were similar for both transplants. Median time
between the 2 ASCTs was 107 days (range 91-145). One patient
with history of gastric bypass died due to liver failure 7 months
after 2nd ASCT. Another patient who completed one ASCT died
due to disease progression (PD) at 806 days after diagnosis. Overall
3 patients had CR and 3 had very good PR (VGPR) after 1st ASCT
(29%), while 5 achieved CR and 1 VGPR after 2nd ASCT with
total of 9/21 (43%) with CRVGPR. At the time of data analysis,
5 of 11 patients who completed only one ASCT showed PD at a
median time of 306 days, while only 3 of 8 patients completing the
2nd ASCT had PD at a median time of 562 days. In conclusion,
tandem autologous transplants result in higher proportion of MM
patients achieving CR, and non-melphalan based conditioning
regimens seem to be effective and safe, however a large number of
patients remain unwilling to proceed to the 2nd ASCT, mainly
because of economical/social reasons.
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FILGRASTIM (GCSF) IS BENEFICIAL AFTER AUTOLOGOUS PERIPHERAL
BLOOD GRAFTS WITH HIGH CD34 CELL CONTENT
Boulmay, B.1, Pazzalia, A.1, Leather, H.L.2, Sugrue, M.2, Wingard,
J.R.1 1. College of Medicine, University of Florida, Gainesville, FL; 2.
Shands at the University of Florida, Gainesville, FL
The 2000 ASCO guidelines recommend the use of colony stim-
ulating factors (CSFs) after autologous peripheral blood stem cell
transplantation (aPBSCT); however, the need for CSFs for pa-
tients (pts) with adequate CD34 cell content in their grafts has
not been established. Prior to 9/01, we initiated GCSF 5mcg/kg of
IBW beginning on D6 only for pts with CD34 doses of less
than 6  106/kg; since 9/01, that threshold was reduced to 4.5 
106/kg. Methods: We conducted a retrospective review of 43
aPBSCT pts from 9/99 through 5/03 with cell doses between
4.5-6  106/kg, 20 of whom had received GCSF (CSF) and 23 of
whom had not (w/o CSF). The groups were matched for age, sex,
diagnosis, prior chemotherapies, conditioning regimens, and mo-
bilization regimens. T-test was used to analyze the data. Results:
CSF pts had signiﬁcantly earlier ANC engraftment, shorter dura-
tion of neutropenia, shorter hospital stays, and fewer days of IV
antibiotics, as shown below in Table. A signiﬁcant difference was
not found for median days of fever, 1 in CSF pts vs 2 in pts w/o
CSF (p 0.31), or median day of platelet engraftment, 13.5 (range
10-74) vs 17 (range 11-30), p  0.29. Signiﬁcantly more pts with
prior radiation therapy (RT) were in the group w/o CSF than in
the CSF group (8 vs 1, p 0.02); however, RT was not found to be
a risk factor for delayed engraftment, prolonged neutropenia, or
length of stay. Conclusion: CSF use in aPBSCT pts with CD34
cell dose 6  106/kg results in earlier engraftment, shorter
neutropenia, and shorter hospital stay. Based on the average
wholesale price of GCSF and the daily cost of hospitalization for
aPBSCT pts, the cost of using GCSF in this population is $1500
per patient vs $4400 for 3 extra days of hospital stay. CSFs should
therefore be used post-aPBSCT in pts with CD34 cell dose6
106/kg.
Table. Effect of G-CSF on Time to Engraftment, Time to Discharge,
Days of Neutropenia and Days of Antibiotic Therapy
Parameter CSF w/o CSF P Value
Median day to ANC > 100
(range) 11 (8-13) 13 (9-15) <0.001
Median day to ANC > 500 11 (10-14) 15 (9-20) <0.001
Median day of discharge 12 (11-18) 15 (12-32) 0.0087
Days of neutropenia 8 (6-15) 12 (8-16) <0.001
Days of IV antibiotics 6 (0-12) 8 (0-13) 0.03
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